BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. rs3825942, FABP1, T cell differentiation, Arthritis, Kidney, Early pregnancy factor)
Bookmark Forward

QuickView for ICI 182,780 (compound)


Genetic Markers

Most Correlated Genes

  1. MCM10
  2. TFF1
  3. UBE2C
  4. DTL
  5. PGR
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_UP
  2. FISCHER_DREAM_TARGETS
  3. DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP
  4. DODD_NASOPHARYNGEAL_CARCINOMA_DN
  5. PUJANA_BRCA1_PCC_NETWORK
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Breast cancer MCF-7 cells treated with selective estrogen receptor modulators
  2. MCF7 breast cancer cells treated with tamoxifen metabolites in the presence or absence of estrogen.
  3. Uterus of COUP-TFII mutant mice treated with oil or ICI 182,780
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Finding the right dose of fulvestrant in breast cancer.
  2. Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups…
  3. Fulvestrant revisited: efficacy and safety of the 500-mg dose.
  4. Economic evaluation of fulvestrant 500 mg versus generic nonsteroidal aromatase inhibitors in patien…
  5. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial canc…
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
  2. ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
  3. Second Line Breast Cancer Trial
  4. Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic …
  5. Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is …
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.